Welcome to our dedicated page for Cheelcare news (Ticker: CHCRF), a resource for investors and traders seeking the latest updates and insights on Cheelcare stock.
Cheelcare Inc. reports news on the commercialization of its advanced mobility products, including the Companion power assist device line and the Curio robotic complex-rehab power wheelchair. Recurring updates cover bookings, unit sales, request-for-quotation activity, dealer engagement, production activity, and reimbursement-supported access for Companion through U.S. Medicare and Medicaid eligibility.
Company news also covers financial results, manufacturing and quality-system updates, investor-conference participation, and capital actions such as unsecured note financing. These developments describe Cheelcare’s role as a Canadian mobility-device manufacturer serving disability, rehabilitation, clinician, therapist, dealer, and funding-agency channels.
Cheelcare (CHCRF) will present at the 2026 Annual Smallcap Discoveries Conference on September 28-29, 2026, at the Parq Hotel & Casino in Vancouver, British Columbia.
CEO Eugene Cherny and VP of Growth Allan Boyd will provide an overview of the company’s business, recent operational and financial milestones, and growth strategy and outlook, and will join one-on-one meetings with investors during the event. The Smallcap Discoveries Conference focuses on commercial-stage Canadian public companies across sectors such as technology, healthcare, industrials, consumer products and business services, and aims to foster long-term investor relationships and support capital formation.
Cheelcare (OTC: CHCRF) reported fiscal 2026 revenue of $1.91 million, up 22% year-over-year, driven by Companion power-assist device sales of 536 units, an 18% increase. Revenue for Q4 2026 rose 78% to $628,407, though the quarter posted a gross loss of $185,033 after a $443,000 inventory write-off and reclassification of assembly labour.
Fiscal 2026 gross profit was $464,525 (24% margin) versus $663,963 (42%) in 2025, and net loss widened to $4.86 million or $0.27 per share, reflecting a $1.34 million reverse takeover listing expense, a $494,238 derivative loss and a $312,209 debt settlement loss. According to Cheelcare, Companion received U.S. Medicare and Medicaid reimbursement eligibility in January 2026, the dealer network expanded to 500+ locations, and over 2,000 Companion units have been sold cumulatively. The company began production in a new 16,000 sq. ft. facility and delivered the first Curio robotic wheelchairs to paying customers while advancing Ontario ADP and U.S. FDA 510(k) regulatory processes.
Cheelcare (TSXV: CHER, OTC: CHCRF) announced it has been invited to present at the Numotion Commercial Growth Summit, held August 12-14, 2026 in Denver, Colorado. The event gathers clinicians, Assistive Technology Professionals, regional decision-makers and industry leaders across Numotion's network.
Cheelcare will showcase its Companion power assist attachment for manual wheelchairs, featuring patented QuickConnect technology and PDAC verification supporting U.S. Medicare and Medicaid reimbursement eligibility. Companion has been named Mobility Management magazine's Product of the Year for three consecutive years. Management views participation as aligned with its strategy to raise awareness among key mobility providers.
Cheelcare (TSXV: CHER, OTC: CHCRF) closed an upsized non-brokered private placement, raising $3,023,250 gross. The offering was increased from $1.5 million to $3.0 million.
The company issued 2,015,500 Units at $1.50, each with one share and half a warrant exercisable at $2.25 for 24 months. Net proceeds fund working capital, product development, and commercialization.
Cheelcare (OTC:CHCRF, TSXV:CHER) upsized its non-brokered private placement to up to 2,000,000 units at $1.50 each for gross proceeds of up to $3,000,000. Each unit includes one share and half a warrant, exercisable at $2.25 for two years.
Proceeds will fund working capital, product development, and commercialization. The financing includes expected insider participation under MI 61-101 exemptions, remains subject to TSX Venture Exchange approval, and the securities will carry a four-month-plus-one-day hold period.
Cheelcare (OTC:CHCRF) announced a non-brokered private placement of up to 1,000,000 units at $1.50 per unit to raise up to $1,500,000.
Each unit includes one share and half a warrant, with warrants exercisable at $2.25 for two years, subject to an acceleration clause. Proceeds will fund working capital, product development, and commercialization, pending TSX Venture Exchange acceptance.
Cheelcare (OTC: CHCRF; TSXV: CHER) received Canadian Patent No. 3090535 for core technologies in its Companion power assist wheelchair platform. The patent, filed August 19, 2020 and issued May 26, 2026, runs 20 years and complements an existing U.S. patent.
The protection covers interface systems that securely and portably attach Companion to manual wheelchairs. According to Cheelcare, this strengthens its IP portfolio, supports long-term commercialization, and aligns with record Companion bookings in March and April 2026, rising RFQ activity, expanding reimbursement access, and a dealer network of 500+ locations and 20+ U.S. VA medical centers.
Cheelcare (OTC:CHCRF) reported preliminary record April 2026 bookings for its Companion power-assist line, marking a second straight monthly record. April bookings rose 147% year-over-year and 38.5% sequentially, supported by rising RFQs after U.S. Medicare and Medicaid reimbursement eligibility gained in January 2026.
Cheelcare (OTC: CHCRF) will present at the 2026 Bloom Burton & Co. Healthcare Investor Conference in Toronto on April 21-22, 2026. The company presentation is scheduled for Wednesday, April 22, 2026 at 3:30 PM ET.
CEO Eugene Cherny and VP of Growth Allan Boyd will deliver the presentation and hold one-on-one investor meetings during the conference.
Cheelcare (OTC: CHCRF) delivered its first Curio robotic complex‑rehab power wheelchairs to paying customers on April 9, 2026, marking a move into commercial production and initial revenue generation for its flagship platform.
The company also reported record Companion unit sales in March, growing Medicare and Medicaid reimbursement uptake, an expanding RFQ pipeline, and a new ~16,000 sq. ft. manufacturing facility and assembly line to support scalable production.